Jin W, Zhong J, Song Y, Li MF, Song SY, Li CR, Hou WW, Li QJ. Chinese herbal formula shen-ling-bai-zhu-san to treat chronic gastritis: Clinical evidence and potential mechanisms. World J Gastroenterol 2022; 28(33): 4890-4908 [PMID: 36156925 DOI: 10.3748/wjg.v28.i33.4890]
Corresponding Author of This Article
Wei-Wei Hou, MD, PhD, Chief Doctor, Department of Emergency, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shierqiao Road, Chengdu 610075, Sichuan Province, China. houww2018@cdutcm.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 7, 2022; 28(33): 4890-4908 Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4890
Chinese herbal formula shen-ling-bai-zhu-san to treat chronic gastritis: Clinical evidence and potential mechanisms
Wei Jin, Juan Zhong, Yang Song, Ming-Fei Li, Shi-Yi Song, Chun-Run Li, Wei-Wei Hou, Qing-Jie Li
Wei Jin, Yang Song, Ming-Fei Li, Wei-Wei Hou, Department of Emergency, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China
Juan Zhong, Shi-Yi Song, Chun-Run Li, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China
Qing-Jie Li, Interventional Operation Room, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China
Author contributions: Jin W and Zhong J designed the protocol; this work was conducted by Jin W, Zhong J, Li QJ, Song Y, and Hou WW; the manuscript was drafted by Zhong J and revised by Li MF, Song SY, and Li CR; Jin W and Zhong J contributed equally to this work and should be regarded as co-first authors; all authors approved the final manuscript before submission.
Conflict-of-interest statement: There are no conflicts of interest to report.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Wei Hou, MD, PhD, Chief Doctor, Department of Emergency, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shierqiao Road, Chengdu 610075, Sichuan Province, China. houww2018@cdutcm.edu.cn
Received: January 12, 2022 Peer-review started: January 12, 2022 First decision: March 8, 2022 Revised: March 16, 2022 Accepted: August 6, 2022 Article in press: August 6, 2022 Published online: September 7, 2022 Processing time: 231 Days and 10.3 Hours
ARTICLE HIGHLIGHTS
Research background
The effects and safety of Shen-ling-bai-zhu san (SLBZS) are currently unclear.
Research motivation
A 2012 clinical practice guideline recommended SLBZ Powder for the Pattern of Spleen and Stomach Deficiency CG. The 2020 clinical guideline did not recommend SLBZS, possibly because of inadequate clinical evidence and pharmacological mechanisms. We designed our study to focus on evidence of efficacy and potential mechanisms. This controversy needed clarified.
Research objectives
To determine the clinical evidence and potential mechanisms of SLBZS for the treatment of CG.
Research methods
Evidence-based meta-analysis and network pharmacology methods.
Research results
Fourteen articles were eventually included, covering 1335 participants. SLBZS might treat CG by acting on related targets and pathways such as EGFR tyrosine kinase inhibitor resistance, the PI3K-Akt signaling pathway, and others.
Research conclusions
SLBZS might be useful in treating CG, but its long-term effects and specific clinical mechanisms keep unclear.
Research perspectives
More samples and high-quality clinical studies should be tested and verified in the next step.
